These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22277680)

  • 1. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
    Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
    Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
    Zheng WL; Zhang GS; Xu YX; Shen JK; Dai CW; Pei MF
    Leuk Res; 2008 Feb; 32(2):251-4. PubMed ID: 17920679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
    Roboz GJ; Ritchie EK; Curcio T; Samuel M; Provenzano J; Segovia J; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Leuk Res; 2011 Apr; 35(4):522-5. PubMed ID: 20956016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
    Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
    Lu J; Jin J; Xu WL
    Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
    Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
    Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
    Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
    Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
    Raza A; Buonamici S; Lisak L; Tahir S; Li D; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G
    Leuk Res; 2004 Aug; 28(8):791-803. PubMed ID: 15203277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
    Ardalan B; Subbarayan PR; Ramos Y; Gonzalez M; Fernandez A; Mezentsev D; Reis I; Duncan R; Podolsky L; Lee K; Lima M; Ganjei-Azar P
    Clin Cancer Res; 2010 Jun; 16(11):3019-27. PubMed ID: 20501625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
    Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
    Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Sekeres MA
    Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
    Zhao WH; Zeng QC; Huang BT; Li BS; Chen RL
    Leuk Res; 2015 Apr; 39(4):424-8. PubMed ID: 25721158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
    Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
    Cancer; 2006 Aug; 107(4):767-72. PubMed ID: 16826578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.